AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia

AACR Special Conference in Cancer Research: Acute Lymphoblastic Leukemia is organized by American Association for Cancer Research (AACR) and will be held from Mar 07 - 09, 2025 at Hilton San Diego Bayfront, San Diego, California, United States of America.

Description:
This conference serves as a crucial forum for advancing research and improving outcomes in acute lymphoblastic leukemia (ALL), a disease with significant unmet needs, particularly in relapsed or refractory cases. With rapid progress in areas such as CAR-T cell therapy, stem cell transplantation, and molecularly targeted therapies, the event will focus on how to effectively integrate these innovations into standard care.

Sessions will explore both B-cell ALL (B-ALL) and T-cell ALL (T-ALL) biology, highlighting the role of cutting-edge diagnostics like genomic profiling and minimal residual disease (MRD) monitoring in personalizing treatment. Discussions will also emphasize the growing importance of immunotherapies in frontline treatment.

As the landscape of ALL therapy evolves, ongoing clinical trials and emerging modalities will be discussed to shape the future of treatment.

The upcoming conference on Acute Lymphoblastic Leukemia (ALL) aims to bridge the gap between scientific research and clinical practice, offering invaluable insights for both scientists and clinicians. Plenary sessions will delve into key areas such as cellular therapies, B-ALL and T-ALL biology, and molecularly targeted therapies, fostering a comprehensive understanding of the disease’s complexities. Discussions on targeted immunotherapies and advancements in diagnostics and prognostics will equip attendees with the latest tools for improving patient outcomes. By exploring future directions in ALL therapy, the conference will encourage collaboration and innovation, ultimately driving progress in treatment strategies. This event promises to serve as a critical platform for sharing knowledge, fostering partnerships, and shaping the future landscape of ALL care.

The conference will address key gaps in acute lymphoblastic leukemia (ALL) research and clinical practice, focusing on the optimal integration of novel therapies like CAR-T and molecularly targeted treatments into standard care. It will bridge understanding between B-cell ALL (B-ALL) and T-cell ALL (T-ALL), explore the personalization of treatment through genomic profiling and minimal residual disease (MRD) monitoring, and clarify the role of immunotherapies in frontline settings. Additionally, discussions will focus on preventing relapse and improving long-term outcomes, translating research into clinical practice, and addressing disparities in access to advanced treatments. By tackling these challenges, the conference aims to foster collaboration and accelerate advancements in ALL therapy.

This educational activity is developed for scientists, researchers and clinicians from across academia and industry involved in studying, treating and understanding Acute Lymphoblastic Leukemia.

After participating in this CME activity, physicians should be able to:

• Formulate treatment plans with combining standard protocols with molecularly targeted therapies.
• Distinguish the subtypes of ALL.
• Articulate the accessibility and equity of ALL care.
• Identify new approaches to diagnose and treat ALL early.
• Demonstrate the necessity of personalized medicine in ALL.

NOTE: On-demand viewing will remain available until May 21, 2025